MedPath

Amiodarone Usage After Ischemic Ventricular Tachycardia Ablation

Conditions
ICD Shock
Ventricular Tachycardia
Ischemic Cardiomyopathy
Registration Number
NCT03244748
Lead Sponsor
Yuksek Ihtisas Hospital
Brief Summary

Ventricular Tachycardia ablation in ischemic cardiomyopathy patients is required procedure in cases when anti-arrhythmic drugs failed. The concern is if adjunctive continuation amiodarone after ablation is needed.

Detailed Description

Ischemic cardiomyopathy patients have implantable cardioverter defibrillators (ICD) to prevent arrhythmic deaths. Ventricular tachycardia (VT) events with frequent ICD interventions in ischemic cardiomyopathy patients is encountered frequently. Frequents ICD interventions is associated with worse outcomes. Anti-arrhythmic drugs ,mostly amiodarone, are given prevent ventricular arrhythmias and ICD interventions that may not be curative. Ablation of ventricular tachycardia is the suggested treatment when anti-drugs are without effect. After ablation of ventricular arrhythmia the continuation of amiodarone is not well elucidated.

In this study we aimed to enroll ischemic cardiomyopathy patients having frequent ICD interventions despite medical treatment. VT ablation is performed and patients divided into two groups; group one continues having amiodarone after ablation, group two does not have amiodarone after ablation. Both groups will be compared in terms of recurrence and death.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
100
Inclusion Criteria

Ischemic cardiomyopathy patients applied with frequent ICD interventionor electrical storms and having ejection fraction below 50%. Frequent ICD defined as more than 1 ICD intervention within month. Electrical storm defined as more than 2 ICD intervention within one day.

Exclusion Criteria

Patients with cardiomyopathies other than ischemic etiology

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Major adverse cardiovascular eventssix months

Death, ICD intervetion

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Turkiye Yuksek Ihtisas Training and Research Hospital

🇹🇷

Ankara, Turkey

Turkiye Yuksek Ihtisas Training and Research Hospital
🇹🇷Ankara, Turkey
Firat Ozcan, Ass. Prof, MD
Contact
5327854000
drfozcan@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.